Current advances in neuromodulation techniques in urology practices: A review of literature

Bulent Erol, Yavuz Onur Danacioglu, Kenneth M Peters, Bulent Erol, Yavuz Onur Danacioglu, Kenneth M Peters

Abstract

Neuromodulation has become a valid therapeutic option for patients with various lower urinary tract disorders. In clinical practice, the most used and recommended neuromodulation techniques are sacral neuromodulation (SNM), pudendal neuromodulation (PN), and percutaneous tibial nerve stimulation (PTNS). There are many theories concerning the mechanism of action of neuromodulation. Although SNM, PN, and PTNS show their activities through different nerve roots, all provide central and peripheral nervous system modulations. SNM has been approved for the treatment of overactive bladder (OAB), nonobstructive urinary retention, and fecal incontinence, while PTNS has been approved for OAB treatment. However, they are also used off-label in other urinary and nonurinary pelvic floor disorders, such as neurogenic lower urinary system disorder, interstitial cystitis, chronic pelvic pain, and sexual dysfunction. Minor and nonsurgical reversible complications are usually seen after neuromodulation techniques. In addition, in the last few years, there have been various developments in neuromodulation technology. Some of the examples of these developments are rechargeable batteries with wireless charging, improvements in programing, less invasive single-stage implantation in outpatient settings, and lower-cost new devices. We performed a literature search using Medline (PubMed), Cochrane Library, EMBASE, and Google scholar databases in the English language from January 2010 to February 2021. We included reviews, meta-analyses, randomized controlled trials, and prospective and retrospective studies to evaluate the activities and reliability of SNM, PN, and PTNS and the developments in this area in the last decade based on the current literature.

Conflict of interest statement

Conflict of Interest: The authors have no conflicts of interest to declare.

References

    1. Yih JM, Killinger KA, Boura JA, Peters KM. Changes in sexual functioning in women after neuromodulation for voiding dysfunction. J Sex Med . 2013;10:(10):2477–2483.. 10.1111/jsm.12085)
    1. Roy H, Offiah I, Dua A. Neuromodulation for pelvic and urogenital pain. Brain Sci . 2018;8:(10):180. 10.3390/brainsci8100180)
    1. Bartley J, Gilleran J, Peters K. Neuromodulation for overactive bladder. Nat Rev Urol . 2013;10:(9):513–521.. 10.1038/nrurol.2013.143)
    1. Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: A clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep . 2012;13:(5):327–334.. 10.1007/s11934-012-0274-9)
    1. Laviana A, Jellison F, Kim J-H. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome. Neurosurg Clin . 2014;25:(1):33–46.. 10.1016/j.nec.2013.08.001)
    1. Peters KM, Killinger KA, Gilleran JP, Bartley J, Wolfert C, Boura JA. Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients. Neurourol Urodynam . 2017;36:(2):354–359.. 10.1002/nau.22929)
    1. Krames ES, Peckham PH, Rezai A, Aboelsaad F. What is Neuromodulation? Neuromodulation . Amsterdam: Elsevier, 2009: 3–8..
    1. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev . 2009;(2):CD004202.
    1. Goldman HB, Lloyd JC, Noblett al. International Continence Society best practice statement for use of sacral neuromodulation. Neurourol Urodyn . 2018;37:(5):1823–1848.. 10.1002/nau.23515)
    1. Tutolo M, Ammirati E, Heesakkers al. Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: A systematic review of the literature. Eur Urol . 2018;73:(3):406–418.. 10.1016/j.eururo.2017.11.002)
    1. El-Azab AS, Siegel SW. Sacral neuromodulation for female pelvic floor disorders. Arab J Urol . 2019;17:(1):14–22.. 10.1080/2090598X.2019.1589930)
    1. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol . 2019;202:(3):558–563.. 10.1097/JU.0000000000000309)
    1. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol . 2015;193:(5):1572–1580.. 10.1016/j.juro.2015.01.087)
    1. Groenendijk IM, Groen J, Scheepe JR, Blok BF. Acute effect of sacral neuromodulation for treatment of detrusor overactivity on urodynamic parameters. Neurourol Urodyn . 2020;39:(2):695–701.. 10.1002/nau.24252)
    1. Blok BF, Groen J, Bosch JR, Veltman DJ, Lammertsma AA. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int . 2006;98:(6):1238–1243.. 10.1111/j.1464-410X.2006.06521.x)
    1. Tutolo M, Ammirati E, Van der Aa F. What is new in neuromodulation for overactive bladder?. Eur Urol Focus . 2018;4:(1):49–53.. 10.1016/j.euf.2018.04.019)
    1. Burks FN, Bui DT, Peters KM. Neuromodulation and the neurogenic bladder. Urol Clin . 2010;37:(4):559–565.. 10.1016/j.ucl.2010.06.007)
    1. Peters KM, Carrico DJ, Perez-Marrero al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: Results from the SUmiT trial. J Urol . 2010;183:(4):1438–1443.. 10.1016/j.juro.2009.12.036)
    1. Siegel S, Noblett K, Mangel al. Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology . 2016;94:57–63.. 10.1016/j.urology.2016.04.024)
    1. Gupta P, Ehlert MJ, Sirls LT, Peters KM. Percutaneous tibial nerve stimulation and sacral neuromodulation: An update. Curr Urol Rep . 2015;16:(2):4. 10.1007/s11934-014-0479-1)
    1. Amundsen CL, Richter HE, Menefee al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: A randomized clinical trial. JAMA . 2016;316:(13):1366–1374.. 10.1001/jama.2016.14617)
    1. Hoag N, Plagakis S, Pillay S, Edwards AW, Gani J. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment. Neurourol Urodynam . 2017;36:(5):1377–1381.. 10.1002/nau.23117)
    1. Moon KH, Han JY, Kim al. Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients. Lower Urinary Tract Symp . 2014;6:(3):175–179.. 10.1111/luts.12036)
    1. Killinger KA, Gupta P, Gilleran al. The impact of baseline functional bladder capacity on short-term neuromodulation outcomes. Urology . 2017;102:68–72.. 10.1016/j.urology.2017.01.008)
    1. Sirls ER, Killinger KA, Boura JA, Peters KM. Percutaneous tibial nerve stimulation in the office setting: Real-world experience of over 100 patients. Urology . 2018;113:34–39.. 10.1016/j.urology.2017.11.026)
    1. Rahnama’i MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. Mult Scler . 2020;26:(11):1274–1280.. 10.1177/1352458519894714)
    1. EAU Guidelines: Edn. Presented at the EAU Annual Congress Amsterdam . ISBN 978-94-92671-07-32020.
    1. Kavia R, DasGupta R, Critchley H, Fowler C, Griffiths D. A functional magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler’s syndrome. BJU Int . 2010;105:(3):366–372.. 10.1111/j.1464-410X.2009.08819.x)
    1. James ND, McMahon SB, Field-Fote EC, Bradbury EJ. Neuromodulation in the restoration of function after spinal cord injury. Lancet Neurol . 2018;17:(10):905–917.. 10.1016/S1474-4422(18)30287-4)
    1. Arlen AM, Powell CR, Kreder KJ. Sacral neuromodulation for refractory urge incontinence is less effective following spinal surgery. Sci World J . 2011;11:142–146.. 10.1100/tsw.2011.13)
    1. Chaabane W, Guillotreau J, Castel‐Lacanal al. Sacral neuromodulation for treating neurogenic bladder dysfunction: Clinical and urodynamic study. Neurourol Urodyn . 2011;30:(4):547–550.. 10.1002/nau.21009)
    1. Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long‐term follow‐up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int . 2014;113:(5):789–794.. 10.1111/bju.12571)
    1. Chan G, Qu LG, Gani J. Evaluation of pre-operative bladder contractility as a predictor of improved response rate to a staged trial of sacral neuromodulation in patients with detrusor underactivity. World J Urol . 2021;39:2113–2117.. 10.1007/s00345-020-03380-z)
    1. Tam J, Loeb C, Grajower D, Kim J, Weissbart S. Neuromodulation for chronic pelvic pain. Curr Urol Rep . 2018;19:(5):1–9.. 10.1007/s11934-018-0783-2)
    1. Mahran A, Baaklini G, Hassani al. Sacral neuromodulation treating chronic pelvic pain: A meta-analysis and systematic review of the literature. Int Urogynecol J . 2019;30:(7):1023–1035.. 10.1007/s00192-019-03898-w)
    1. Gupta P, Gaines N, Sirls LT, Peters KM. A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: An ideal model of care. Transl Androl Urol . 2015;4:(6):611–619.. 10.3978/j.issn.2223-4683.2015.10.10)
    1. Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: Long‐term follow‐up. Neurourol Urodyn . 2011;30:(7):1271–1275.. 10.1002/nau.21037)
    1. Martellucci J, Naldini G, Carriero A. Sacral nerve modulation in the treatment of chronic pelvic pain. Int J Colorectal Dis . 2012;27:(7):921–926.. 10.1007/s00384-011-1394-2)
    1. Gonzalez EJ, Grill WM. Sensory pudendal nerve stimulation increases bladder capacity through sympathetic mechanisms in cyclophosphamide‐induced cystitis rats. Neurourol Urodyn . 2019;38:(1):135–143.. 10.1002/nau.23860)
    1. Peters KM, Killinger KA, Jaeger C, Chen C. Pilot study exploring chronic pudendal neuromodulation as a treatment option for pain associated with pudendal neuralgia. Lower Urinary Tract Symp . 2015;7:(3):138–142.. 10.1111/luts.12066)
    1. Colemeadow J, Sahai A, Malde S. Clinical management of bladder pain syndrome/interstitial cystitis: A review on current recommendations and emerging treatment options. Res Rep Urol . 2020;12:331–343.. 10.2147/RRU.S238746)
    1. Cottrell AM, Schneider MP, Goonewardene al. Benefits and harms of electrical neuromodulation for chronic pelvic pain: A systematic review. Eur Urol Focus . 2020;6:559–571.. 10.1016/j.euf.2019.09.011)
    1. Homma Y, Akiyama Y, Tomoe al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol . 2020;27:(7):578–589.. 10.1111/iju.14234)
    1. Signorello D, Seitz CC, Berner al. Impact of sacral neuromodulation on female sexual function and his correlation with clinical outcome and quality of life indexes: A monocentric experience. J Sex Med . 2011;8:(4):1147–1155.. 10.1111/j.1743-6109.2010.02189.x)
    1. Khunda A, McCormick C, Ballard P. Sacral neuromodulation and sexual function: A systematic review and meta-analysis of the literature. Int Urogynecol J . 2019;30:(3):339–352.. 10.1007/s00192-018-3841-x)
    1. Jadav A, Wadhawan H, Jones G, Wheldon L, Radley S, Brown S. Does sacral nerve stimulation improve global pelvic function in women?. Colorectal Dis . 2013;15:(7):848–857.. 10.1111/codi.12181)
    1. de Oliveira PS, Reis JP, de Oliveira al. The impact of sacral neuromodulation on sexual dysfunction. Curr Urol . 2019;12:(4):188–194.. 10.1159/000499307)
    1. Lombardi G, Agrò EF, Del Popolo G. Sacral neuromodulation and female sexuality. Int Urogynecol J . 2015;26:(12):1751–1757.. 10.1007/s00192-015-2708-7)
    1. Kwon MH, Park SH, Song al. Penile erection induces angiogenic, survival, and antifibrotic signals: Molecular events associated with penile erection induced by cavernous nerve stimulation in mice. Int J Urol . 2016;23:(7):614–622.. 10.1111/iju.13105)
    1. Hox M, Mann-Gow T, Lund L, Zvara P. Cavernous nerve stimulation and recording of intracavernous pressure in a rat. J Vis Exp . 2018;(134):56807. 10.3791/56807)
    1. Blok B, Van Kerrebroeck P, de Wachter al. Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn . 2018;37:(S2):S17–S22.. 10.1002/nau.23476)
    1. Jaqua K, Powell CR. Where are we headed with neuromodulation for overactive bladder?. Curr Urol Rep . 2017;18:(8):1–6.. 10.1007/s11934-017-0711-x)

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere